Tina Dalianis1, Nathalie Grün2, Jana Koch2, Andrea Vlastos3, Nikolaos Tertipis2, Cecilia Nordfors2, Anders Näsman2, Malin Wendt4, Mircea Romanitan5, Cinzia Bersani2, Eva Munck-Wikland4, Torbjörn Ramqvist2. 1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: Tina.Dalianis@ki.se. 2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Audiology and Neurotology, Karolinska University Hospital, Stockholm, Sweden.
Abstract
OBJECTIVES: Hypopharyngeal cancer is a subset of head neck squamous cell carcinoma (HNSCC) with particularly poor prognosis. Human papillomavirus (HPV) is a risk factor for some HNSCC, and its presence is of prognostic value for certain subsites. However, its influence on survival in hypopharyngeal cancer has not been thoroughly investigated. Here we examine HPV DNA and p16(INK4a) (p16) overexpression in relation to clinical outcome. MATERIALS AND METHODS: Hypopharyngeal tumour biopsies from 82 patients diagnosed 2008-2013 were examined for presence of HPV DNA by a bead-based multiplex assay and for p16 expression by immunohistochemistry, and the obtained data compared to that acquired previously from 109 patients diagnosed 2000-2007 at the same clinic. A survival analysis was then performed on 142 patients (from both studies) treated with curative intent and a 3-year follow-up time. RESULTS: Of the tumour biopsies 3/82 (3.7%) were HPV16 DNA and p16 positive, while 12/82 (14.6%) were p16 positive, equivalent to that in the previous study. Overall 3-year survival was significantly more favourable for patients with HPV16 DNA and p16 positive tumours as compared to survival of the other patients (86% vs. 31%, p=0.0185). A similar but not statistically significant trend was found for disease specific survival. CONCLUSION: HPV DNA and p16 positive hypopharyngeal cancer was rare and had not increased, but had a better clinical outcome as compared to other HPV-unrelated hypopharyngeal cancer. In addition, p16 overexpression was not a suitable surrogate marker for presence of HPV or for prediction of survival in this type of cancer.
OBJECTIVES:Hypopharyngeal cancer is a subset of head neck squamous cell carcinoma (HNSCC) with particularly poor prognosis. Human papillomavirus (HPV) is a risk factor for some HNSCC, and its presence is of prognostic value for certain subsites. However, its influence on survival in hypopharyngeal cancer has not been thoroughly investigated. Here we examine HPV DNA and p16(INK4a) (p16) overexpression in relation to clinical outcome. MATERIALS AND METHODS:Hypopharyngeal tumour biopsies from 82 patients diagnosed 2008-2013 were examined for presence of HPV DNA by a bead-based multiplex assay and for p16 expression by immunohistochemistry, and the obtained data compared to that acquired previously from 109 patients diagnosed 2000-2007 at the same clinic. A survival analysis was then performed on 142 patients (from both studies) treated with curative intent and a 3-year follow-up time. RESULTS: Of the tumour biopsies 3/82 (3.7%) were HPV16 DNA and p16 positive, while 12/82 (14.6%) were p16 positive, equivalent to that in the previous study. Overall 3-year survival was significantly more favourable for patients with HPV16 DNA and p16 positive tumours as compared to survival of the other patients (86% vs. 31%, p=0.0185). A similar but not statistically significant trend was found for disease specific survival. CONCLUSION:HPV DNA and p16 positive hypopharyngeal cancer was rare and had not increased, but had a better clinical outcome as compared to other HPV-unrelated hypopharyngeal cancer. In addition, p16 overexpression was not a suitable surrogate marker for presence of HPV or for prediction of survival in this type of cancer.
Authors: Lars Sivars; Cinzia Bersani; Nathalie Grün; Torbjörn Ramqvist; Eva Munck-Wikland; Christian Von Buchwald; Tina Dalianis Journal: Mol Clin Oncol Date: 2016-10-13
Authors: Gypsyamber D'Souza; Devasena Anantharaman; Tarik Gheit; Behnoush Abedi-Ardekani; Daniel C Beachler; David I Conway; Andrew F Olshan; Victor Wunsch-Filho; Tatiana N Toporcov; Wolfgang Ahrens; Kathy Wisniewski; Franco Merletti; Stefania Boccia; Eloiza H Tajara; Jose P Zevallos; José Eduardo Levi; Mark C Weissler; Sylvia Wright; Ghislaine Scelo; Angela L Mazul; Massimo Tommasino; Gabriella Cadoni; Paul Brennan Journal: Oral Oncol Date: 2016-09-26 Impact factor: 5.337
Authors: Sibo Tian; Jeffrey M Switchenko; Jaymin Jhaveri; Richard J Cassidy; Matthew J Ferris; Robert H Press; Neil T Pfister; Mihir R Patel; Nabil F Saba; Mark W McDonald; Kristin A Higgins; David S Yu; Walter J Curran; Theresa W Gillespie; Jonathan J Beitler Journal: Cancer Date: 2019-04-23 Impact factor: 6.860
Authors: Deborah C Marshall; Derek D Kao; Richard Bakst; Sonam Sharma; Rocco Ferrandino; Kenneth Rosenzweig; Juan Wisnivesky; Keith Sigel Journal: Laryngoscope Investig Otolaryngol Date: 2020-08-11
Authors: Andre Isaac; Morris Kostiuk; Han Zhang; Cameron Lindsay; Fawaz Makki; Daniel A O'Connell; Jeffrey R Harris; David W J Cote; Hadi Seikaly; Vincent L Biron Journal: J Otolaryngol Head Neck Surg Date: 2017-01-14
Authors: Andreas Ährlund-Richter; Liqin Cheng; Yue O O Hu; Mikaela Svensson; Alexandra A L Pennhag; Ramona G Ursu; Linnea Haeggblom; Nathalie Grün; Torbjörn Ramqvist; Lars Engstrand; Tina Dalianis; Juan Du Journal: Front Cell Infect Microbiol Date: 2019-03-20 Impact factor: 5.293
Authors: Anna Janecka-Widła; Anna Mucha-Małecka; Kaja Majchrzyk; Krzysztof Halaszka; Marcin Przewoźnik; Dorota Słonina; Beata Biesaga Journal: J Cancer Res Clin Oncol Date: 2020-05-05 Impact factor: 4.553